SUBSTITUTED 1-INDOLYLPROPYL-4-PHENETHYLPIPERAZINE DERIVATIVES

Abstract: A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, and on the phenyl ring of the phenethyl moiety by fluoro, chloro, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D alpha receptor subtype whilst possessing at least a 10-fold selective affinity for th e5-HT1D alpha receptor subtype relative to the 5-HT1D beta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

Description: SUBSTITUTED l-INDOLYLPROPYL-4-PHENETHYLPIPERAZINE DERIVATIVES The present invention relates to a class of substituted piperazine derivatives which act on 5-hydroxytryptamine (5-HT) receptors, being selective agonists of so-called "5-HTι-like" receptors. They are therefore useful in the treatment of clinical conditions for which a selective agonist of these receptors is indicated. It has been known for some time that 5-HTι-like receptor agonists which exhibit selective vasoconstrictor activity are of use in the treatment of migraine (see, for example, A. Doenicke et al, The Lancet, 1988, Vol. 1, 1309-11; and W. Feniuk and P.P.A. Humphrey, Drug Development Research, 1992, 26, 235-240). The human 5-HTι-like or 5-HTID receptor has recently been shown by molecular cloning techniques to exist in two distinct subtypes. These subtypes have been termed 5-HTiD α (or 5-HTID-I) and 5-HTID P (or 5-HTID-2), and their amino acid sequences are disclosed and claimed in WO-A- 91/17174. The 5-HTiDα receptor subtype in humans is believed to reside on sensory terminals in the dura mater. Stimulation of the 5-HTID <X subtype inhibits the release of inflammatory neuropeptides which are thought to contribute to the headache pain of migraine. The human 5-HTiDp receptor subtype, meanwhile, is located predominantly on the blood vessels and in the brain, and hence may play a part in mediating constriction of cerebral and coronary arteries, as well as CNS effects. Administration of the prototypical 5-HTID agonist sumatriptan (GR43175) to humans is known to give rise at therapeutic doses to certain adverse cardiovascular events (see, for example, F. Willett et al., Br. Med. J., 1992, 304, 1415; J.P. Ottervanger et al, The Lancet, 1993, 341, 861-2; and D.N. Bateman, The Lancet, 1993, 341, 221-4). Since sumatriptan barely discriminates between the human 5-HTiD α and 5-HTιυj? receptor subtypes (cf. WO-A-91/17174, Table 1), and since it is the blood vessels with which the 5-HTiDp subtype is most closely associated, it is bebeved that the cardiovascular side-effects observed with sumatriptan can be attributed to stimulation of the 5-HTID P receptor subtype. It is accordingly considered (cf. G.W. Rebeck et al, Proc. Natl. Acad. Sci. USA, 1994, 91, 3666-9) that compounds which can interact selectively with the 5-HTiD α receptor subtype, whilst having a less pronounced action at the 5-HTiDp subtype, might be free from, or at any rate less prone to, the undesirable cardiovascular and other side-effects associated with non-subtype-selective 5-HTID receptor agonists, whilst at the same time maintaining a beneficial level of anti -migraine activity. The compounds of the present invention, being selective 5-HTι-like receptor agonists, are accordingly of benefit in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine. In particular, the compounds according to this invention are potent agonists of the human 5-HTiD α receptor subtype. Moreover, the compounds in accordance with this invention have been found to possess at least a 10-fold selective affinity for the 5-HTID < _ receptor subtype relative to the 5-HT p subtype, and they can therefore be expected to manifest fewer side-effects than those associated with non-subtype-selective 5-HTID receptor agonists. Several distinct classes of substituted five-membered heteroaromatic compounds are described in published European patent apphcation 0497512, and published International patent apphcations 93/18029, 94/02477 and 94/03446. The compounds described therein are stated to be agonists of 5-HTι-like receptors, and accordingly to be of particular use in the treatment of migraine and associated conditions. None of these publications, however, discloses nor even suggests the substituted piperazine derivatives provided by the present invention. In EP-A-0548813 is described a series of alkoxypyridin-4-yl and alkoxypyrimidin-4-yl derivatives of indol-3-ylalkylpiperazines which are alleged to provide treatment of vascular or vascular-related headaches, including migraine. There is, however, no disclosure nor any suggestion in EP-A-0548813 of replacing the alkoxypyridine or alkoxypyrimidine substituent with a substituted phenylethyl moiety; nor is there any suggestion therein that the range of substituents specified at the 5-position of the indole moiety might be replaced by an imidazole or triazole ring. Moreover, nowhere in the prior art mentioned above is there any disclosure of a subtype-selective 5-HTID receptor agonist having a 5-HTiD α receptor binding affinity (ICso) below 50 nM and at least a 10-fold selective affinity for the 5-HTID 0 receptor subtype relative to the 5-HTiDp subtype. The compounds according to the present invention are subtype- selective 5-HTID receptor agonists having a human 5-HTiD α receptor binding affinity (ICso) below 50 nM, typically below 10 nM and preferably below 1 nM; and at least a 10-fold selective affinity, typically at least a 50- fold selective affinity and preferably at least a 100-fold selective affinity, for the human 5-HTiD α receptor subtype relative to the 5-HTiDp subtype. Moreover, the compounds in accordance with this invention possess interesting properties in terms of their efficacy and/or bioavailability. The present invention provides a compound of formula I, or a salt or prodrug thereof: wherein X represents a group of formula (Xa), (Xb) or (Xc): N^\ N^\ N ' Y s I N— I N-CH 2 — I N— (Xa) (Xb) (Xc) in which Y represents nitrogen or C-R 4 ; R 1 represents fluoro, chloro, trifluoromethyl, Ci-β alkoxy or a group of formula (a): (a) R 2 and R 3 independently represent hydrogen, halogen, trifluoromethyl or Ci e alkoxy; and R 4 represents hydrogen or Ci-β alkyl. The present invention also provides a compound of structural formula I above, or a salt or prodrug thereof, wherein X represents a group of formula (Xa) as defined above, and R 1 , R 2 and R 3 are as defined above. The compounds in accordance with the present invention are encompassed within the generic scope of co-pending International Patent Apphcation No. PCT/GB95/01129, published as WO 95/32196 on 30 November 1995. There is, however, no specific disclosure therein of compounds corresponding to those of formula I as defined above. As used herein, the expression "CI-G alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and tert-butyl. Derived expressions such as "Ci-e alkoxy" are to be construed accordingly. The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine. For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxahc acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Particular acid addition salts of the compounds in accordance with the invention include the oxalate and maleate salts, typically the hydrogen oxalate and dihydrogen maleate salts, and especially the dihydrogen maleate salt. A preferred class of acid addition salts of the compounds according to the present invention comprises the citrate salts, in particular the dicitrate salt. The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985. Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention. In the compounds of formula I above, the moiety X preferably represents a group of formula (Xa) as depicted above. Suitably, the variable Y in formula (Xc) represents nitrogen, CH or C-methyl. In the compounds of formula I above, the moiety R 1 suitably represents fluoro, trifluoromethyl, methoxy or a group of formula (a) as defined above. Particular values of R 1 include fluoro and trifluoromethyl, especially fluoro. Suitably, R 2 and R 3 independently represent hydrogen, fluoro, trifluoromethyl or methoxy, in particular hydrogen or fluoro. Suitably, one or both of R 2 and R 3 represents hydrogen. Suitably, R 4 represents hydrogen or methyl. A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof: (IIA) wherein R 1 , R 2 and R 3 are as defined above. Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and salts and prodrugs thereof: (IIB) wherein R 1 , R 2 and R 3 are as defined above. A further sub-class of compounds according to the invention is represented by the compounds of formula IIC, and salts and prodrugs thereof: wherein Y 1 represents nitrogen, CH or C-methyl; and R 1 , R 2 and R 3 are as defined above. Particular values of R 1 in relation to formulae IIA, IIB and IIC above include fluoro and trifluoromethyl, especially fluoro. In one embodiment of the compounds of formulae IIA, IIB and IIC above, R 2 is hydrogen and R 3 is other than hydrogen. In another embodiment of the compounds of formulae IIA, IIB and IIC above, R 2 and R 3 are both hydrogen. In relation to formula IIC, Y 1 is suitably CH or C-methyl. Specific compounds within the scope of the present invention include: l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(2-fluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)- ethyljpip er azine ; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-methoxyphenyl)- ethyl]pip er azine ; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-trifluoromethyl- phenyl)ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)- ethyljpiperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(2,4-difluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3,5-difluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-(oxazohdin-2-on-3- yl)phenyl)ethyl]piperazine; l-[3-(5-(imidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)- ethyl]piperazine; l-[3-(5-(imidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)- ethyl]piperazine; l-[3-(5-(2-methyhmidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3- fluorophenyl)ethyl]piperazine; l-[3-(5-(l,2,4-triazol-l-ylmethyl)-lH-indol-3-yl)propyl]-4-[2-(3,4- difluoropheny 1) ethyl] pip er azine ; l-[3-(5-(2-methyΗmidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4- difluorophenyl) ethyl] pip er azine ; l-[3-(5-(l,2,4-triazol-l-ylmethyl)-lH-indol-3-yl)propyl]-4-[2-(3- fluorophenyl)ethyl]piperazine; and salts and prodrugs thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or hquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing sohd compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a sohd preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This sohd preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. The hquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin. In the treatment of migraine, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day. The compounds according to the invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV: (HI) (IV) wherein X, R 1 , R 2 and R 3 are as defined above, and L 1 represents a suitable leaving group. The leaving group L 1 is suitably a halogen atom, e.g. chlorine or bromine, or an alkylsulphonyloxy or arylsulphonyloxy group, e.g. methanesulphonyloxy (mesyloxy) or p-toluenesulphonyloxy (tosyloxy). The reaction between compounds III and IV is conveniently effected by stirring the reactants under basic conditions in a suitable solvent, for example triethylamine or potassium carbonate in Λ -V-dimethylformamide or in isopropanol and or 1,2-dimethoxyethane, typically in the presence of sodium iodide. In another procedure, the compounds according to the invention may be prepared by a process which comprises reacting a compound of formula III as defined above with a compound of formula V: wherein R 1 , R 2 and R 3 are as defined above; in the presence of a reducing agent. A suitable reducing agent for effecting this process is sodium cyanoborohydride, and the reaction is conveniently carried out in methanol, typically in the presence of acetic acid, at room temperature. In a further procedure, the compounds according to the invention may be prepared by a process which comprises reacting a compound of formula III as defined above with a carboxyhc acid derivative of formula VI: (VI) wherein R 1 , R 2 and R 3 are as defined above; in the presence of a condensing agent; followed by treatment with a reducing agent such as diisobutylaluminium hydride. A suitable condensing agent for use in conjunction with the above process comprises l-(3-dimethylaminopropyl)-3-ethylcarbodi_mide and 1 -hydroxybenzotriazole hydrate. The compounds of formula III above may be prepared by a process which comprises reacting the appropriate compound of formula VII: ( vii ) wherein X is as defined above; with a compound of formula VIII, or a carbonyl-protected form thereof: VHD wherein R p represents an amino-protecting group; with subsequent removal of the amino-protecting group RP. The reaction between compounds VTI and VIII, which is an example of the well-known Fischer indole synthesis, is suitably carried out by heating the reagents together under mildly acidic conditions, e.g. 4% sulphuric acid at reflux. Suitable carbonyl-protected forms of the compounds of formula VIII include the dimethyl acetal derivatives. The protecting group R in the compounds of formula VIII is suitably a carbamoyl moiety such as tert-butoxycarbonyl (BOC), which can conveniently be removed as necessary by treatment under mildly acidic conditions. Indeed, the acidic conditions of the Fischer indole synthesis reaction will generally suffice to remove the BOC group. The Fischer reaction between compounds VII and VIII may be carried out in a single step, or may proceed via an initial non-cychsing step at a lower temperature to give an intermediate of formula IX: (IX) wherein X and RP are as defined above; followed by cychsation using a suitable reagent, e.g. a polyphosphate ester. The intermediates of formula VIII, or carbonyl-protected forms thereof, may be prepared by reacting a compound of formula X, or a carbonyl-protected form thereof, with a compound of formula XI: (X) (XI) wherein RP is as defined above, and L 2 represents a suitable leaving group. The leaving group L 2 is suitably a halogen atom, e.g. chlorine or bromine. Where L 2 represents a halogen atom, the reaction between compounds X and XI is conveniently effected by stirring the reactants under basic conditions in a suitable solvent, for example potassium carbonate in 1,2-dimethoxyethane or N.N-dimethylformamide, or triethylamine in tetrahydrofuran or acetonitrile, typically in the presence of sodium iodide. The compounds according to the invention may alternatively be prepared by a process which comprises reacting the appropriate compound of formula VII as defined above with a compound of formula XII, or a carbonyl-protected form thereof: wherein R 1 , R 2 and R 3 are as defined above; under conditions analogous to those described above for the reaction between compounds VII and VIII. As for the compounds of formula VIII, suitable carbonyl-protected forms of the compounds of formula XII include the dimethyl acetal derivatives. As with that between compounds VII and VIII, the Fischer reaction between compounds VII and XII may be carried out in a single step, or may proceed via an initial non-cychsing step at a lower temperature to give an intermediate of formula XIII: wherein X, R 1 , R 2 and R 3 are as defined above; followed by cychsation using a suitable reagent, e.g. a polyphosphate ester. The intermediates of formula XII, or carbonyl-protected forms thereof, may be prepared by reacting a compound of formula X as defined above, or a carbonyl-protected form thereof, with a compound of formula XIV: (XIV) wherein R 1 , R 2 and R 3 are as defined above; under conditions analogous to those described above for the reaction between compounds X and XI. In an alternative procedure, the compounds of formula III above may be prepared by a process which comprises reacting a compound of formula XI as defined above with a compound of formula XV: (XV) wherein X is as defined above, and L 3 represents a suitable leaving group; followed by removal of the amino-protecting group R p . Similarly, the compounds of formula I as defined above may be prepared by a process which comprises reacting a compound of formula XIV as defined above with a compound of formula XV as defined above. The leaving group L 3 is suitably an alkylsulphonyloxy or arylsulphonyloxy group, e.g. methanesulphonyloxy (mesyloxy) or p -toluenesulphonyloxy (tosyloxy) . Where L 3 represents an alkylsulphonyloxy or arylsulphonyloxy group, the reaction between compound XV and compound XI or XIV is conveniently carried out in a suitable solvent such as tetrahydrofuran, 1,2-dimethoxyethane or isopropyl alcohol, typically in the presence of a base such as sodium carbonate or potassium carbonate, optionally with the addition of sodium iodide. In one representative approach, the compounds of formula XV wherein L 3 represents a mesyloxy or tosyloxy group may be prepared by the sequence of steps illustrated in the following reaction scheme (cf. Larock and Yum, J. Am. Chem. Soc, 199i; 113, 6689): (XVI) wherein X is as defined above, L 4 represents mesyloxy or tosyloxy, and TMS is an abbreviation for trimethylsilyl. In Step 1 of the reaction scheme, the aniline derivative XVI is treated with iodine monochloride, advantageously in methanol in the presence of a base such as calcium carbonate, in order to introduce an iodine atom ortho to the amine moiety. Step 2 involves a palladium- mediated couphng reaction with the protected acetylene derivative TMS-C-≡C-(CH 2 )3-OH, typically using palladium acetate and triphenylphosphine in the presence of hthium chloride and sodium carbonate, suitably in N,_V-dimethylformamide at an elevated temperature. This is followed in Step 3 by removal of the TMS moiety, ideally in refluxing methanohc hydrochloric acid; followed in turn by mesylation or tosylation, suitably by using mesyl chloride or tosyl chloride respectively, in pyridine or triethylamine/tetrahydrofuran. In another representative approach, the compounds of formula XV wherein L 3 represents a mesyloxy or tosyloxy group may be prepared by reacting 3,4-dihydro-2H-pyran with the appropriate compound of formula VII as defined above or a salt thereof, under a variant of the Fischer reaction conditions as described above for the reaction between compounds VII and VIII; followed by mesylation or tosylation of the 3-hydroxypropyl- indole derivative thereby obtained, typically by treatment with mesyl chloride or tosyl chloride under standard conditions. The Fischer reaction with 3,4-dihydro-2H-pyran is suitably brought about by heating the appropriate hydrazine derivative VII or an acid addition salt thereof, typically the hydrochloride salt, in an inert solvent such as dioxan, advantageously in the presence of a mineral acid such as hydrochloric acid or a Lewis acid such as zinc chloride, at the reflux temperature of the solvent. In a yet further procedure, the compounds of formula III above may be prepared by a process which comprises reducing a compound of formula XVII: (XVII) wherein X and R are as defined above; with subsequent removal of the amino-protecting group R p . Si ilarly, the compounds according to the invention may be prepared by a process which comprises reducing a compound of formula XVTII: (XVIII) wherein X, R 1 , R 2 and R 3 are as defined above. The reduction of compound XVII or compound XVIII is conveniently effected by treating the appropriate compound with a reducing agent such as hthium aluminium hydride in an appropriate solvent, e.g. diethyl ether or tetrahydrofuran, or mixtures thereof. The compounds of formulae XVII and XVIII above may suitably be prepared by reacting the appropriate compound of formula XI or XIV with a compound of formula XIX: (XIX) wherein X is as defined above, and J represents a reactive carboxylate moiety. Suitable values for the reactive carboxylate moiety J include esters, for example Cι- 4 alkyl esters; acid anhydrides, for example mixed anhydrides with Cι- alkanoic acids; acid halides, for example acid chlorides; and acylimidazoles. By way of example, the intermediates of formula XIX above wherein J is an acid chloride moiety may be prepared by treating the corresponding carboxyhc acid derivative with thionyl chloride in toluene. Si-milarly, the intermediates of formula XIX wherein J is an acylimidazole moiety may be prepared by treating the corresponding carboxyhc acid derivative with 1,1 '-carbonyldiimidazole. Alternatively, the reactive carboxylate moiety J may be obtained by treating the corresponding compound wherein J is carboxy with l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, optionally in the presence of triethylamine; the resulting activated carboxylate intermediate may then suitably be reacted in situ with the required compound of formula XI or XTV. The hydrazine derivatives of formula VII above can be prepared by the methods described in EP-A-0497512 and WO-A-94/03446, as also can the aniline derivatives of formula XVI. Where they are not commercially available, the starting materials of formula IV, V, VI, X, XI, XIV and XIX may be prepared by methods analogous to those described in the accompanying Examples, or by standard procedures well known from the art. Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di- .-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. The following Examples illustrate the preparation of compounds according to the invention. The compounds in accordance with the present invention potently and selectively bind to the 5-HTID 0 receptor subtype, inhibit forskolin- stimulated adenylyl cyclase activity, and stimulate [ 35 S]-GTPγS binding to membranes from clonal cell hnes expressing human cloned receptors. 5-HTID„/5-HTID P Radioligand Binding Chinese hamster ovary (CHO) clonal cell hnes expressing the human 5-HTID < _ and 5-HTID P receptors were harvested in PBS and homogenised in ice cold 50 mM Tris-HCl (pH 7.7 at room temperature) with a Kinematica polytron and centrifuged at 48,000g at 4°C for 11 min. The pellet was then resuspended in 50 mM Tris-HCl followed by a 10 min incubation at 37°C. Finally the tissue was recentrifuged at 48,000g, 4°C for 11 min and the pellet resuspended, in assay buffer (composition in mM: Tris-HCl 50, pargyline 0.01, CaCl 2 4; ascorbate 0.1%; pH 7.7 at room temperature) to give the required volume immediately prior to use (0.2 mg protein/ml). Incubations were carried out for 30 min at 37°C in the presence of 0.02-150 nM [ 3 H]-5-HT for saturation studies or 2-5 nM [ 3 H]-5- HT for displacement studies. The final assay volume was 1 ml. 5-HT (10 μM) was used to define non-specific binding. The reaction was initiated by the addition of membrane and was terminated by rapid filtration through Whatman GF/B filters (presoaked in 0.3% PEI/ 0.5% Triton X) foUowed by 2 x 4 ml washings with 50 mM Tris-HCl. The radioactive filters were then counted on a LKB beta or a WaUac beta plate counter. Binding parameters were determined by non-linear, least squares regression analysis using an iterative curve fitting routine, from which ICso (the molar concentration of compound necessary to inhibit binding by 50%) values could be calculated for each test compound. The ICso values for binding to the 5-HTID < _ receptor subtype obtained for the compounds of the accompanying Examples were below 50 nM in each case. Furthermore, the compounds of the accompanying Examples were aU found to possess a selective affinity for the 5-HTiD α receptor subtype of at least 10-fold relative to the 5-HTiDp subtype. 5-HT-D<J5-HTiDp Adenylyl Cyclase Assay Studies were performed essentially as described in J. Pharmacol. Exp. Ther., 1986, 238, 248. CHO clonal ceU hnes expressing the human cloned 5-HT α and 5-HT p receptors were harvested in PBS and homogenised, using a motor driven teflon/glass homogeniser, in ice cold Tris HC1-EGTA buffer (composition in mM: Tris HCl 10, EGTA 1, pH 8.0 at room temperature) and incubated on ice for 30-60 min. The tissue was then centrifuged at 20,000g for 20 min at 4°C, the supernatant discarded and the peUet resuspended in Tris HC1-EDTA buffer (composition in mM: Tris HCl 50, EDTA 5, pH 7.6 at room temperature) just prior to assay. The adenylyl cyclase activity was determined by measuring the conversion of -[ 33 P]-ATP to [ 33 P]-cychc AMP. A 10 μl aliquot of the membrane suspension was incubated, for 10-15 min, in a final volume of 50 μl, at 30°C, with or without forskolin (10 μM), in the presence or absence of test compound. The incubation buffer consisted of 50 mM Tris HCl (pH 7.6 at room temperature), 100 mM NaCl, 30 μM GTP, 50 μM cychc AMP, 1 mM dithiothreitol, 1 mM ATP, 5 mM Mg CL, 1 mM EGTA, 1 mM 3-isobutyl-l- methylxanthine, 3.5 mM creatinine phosphate, 0.2 mg/ml creatine phosphokinase, 0.5-1 μCi α-[ 33 P]-ATP and 1 nCi [ 3 H]-cychc AMP. The incubation was initiated by the addition of membrane, foUowing a 5 min preincubation at 30°C, and was terminated by the addition of 100 μl SDS (composition in mM: sodium lauryl sulphate 2%,. ATP 45, cychc AMP 1.3, pH 7.5 at room temperature). The ATP and cychc AMP were separated on a double column chromatography system (Anal. Biochem., 1974, 58, 541). Functional parameters were determined using a least squares curve fitting programme ALLFIT (Am. J. Physiol, 1978, 235, E97) from which Ema (maximal effect) and ECso (the molar concentration of compound necessary to inhibit the maximal effect by 50%) values were obtained for each test compound. Of those compounds which were tested in this assay, the ECso values for the 5-HTiD α receptor obtained for the compounds of the accompanying Examples were below 500 nM in each case. Moreover, the compounds of the accompanying Examples which were tested were aU found to possess at least a 10-fold selectivity for the 5-HTID 0 receptor subtype relative to the 5-HTID P subtype. 5-HTiD„/5-HTiD P GTPγS Binding Studies were performed essentiaUy as described in Br. J. Pharmacol., 1993, 109, 1120. CHO clonal ceU hnes expressing the human cloned 5-HTiD α and 5-HTID P receptors were harvested in PBS and homogenised using a Kinematica polytron in ice cold 20 mM HEPES containing 10 mM EDTA, pH 7.4 at room temperature. The membranes were then centrifuged at 40,000g, 4°C for 15 min. The peUet was then resuspended in ice cold 20 mM HEPES containing 0.1 mM EDTA, pH 7.4 at room temperature and recentrifuged at 40,000g, 4°C for 15-25 minutes. The membranes were then resuspended in assay buffer (composition in mM: HEPES 20, NaCl 100, MgCl 2 10, pargyline 0.01; ascorbate 0.1%; pH 7.4 at room temperature) at a concentration of 40 μg protein/ml for the 5-HTiDα receptor transfected ceUs and 40-50 μg protein/ml for the 5-HTiDp receptor transfected ceUs. The membrane suspension was then incubated, in a volume of 1 ml, with GDP (100 μM for 5-HTID« receptor transfected ceUs, 30 μM for the 5-HT p receptor transfected ceUs) and test compound at 30°C for 20 min and then transferred to ice for a further 15 min. [ 35 S]-GTPγS was then added at a final concentration of 100 pM and the samples incubated for 30 min at 30°C. The reaction was initiated by the addition of membrane and was terminated by rapid filtration through Whatman GF/B filters and washed with 5 ml water. The radioactive filters were then counted on a LKB beta counter. Functional parameters were determined by a non-hnear, least squares regression analysis using an iterative curve fitting routine, from which E ma χ (maximal effect) and ECso (the molar concentration of compound necessary to inhibit the maximal effect by 50%) values were obtained for each test compound. Of those compounds which were tested in this assay, the ECso values for the 5-HTiDα receptor obtained for the compounds of the accompanying Examples were below 500 nM in each case. Moreover, the compounds of the accompanying Examples which were tested were aU found to possess at least a 10-fold selectivity for the 5-HTID« receptor subtype relative to the 5-HTiDp subtype. EXAMPLE 1 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)Dropyll-4-r2-(3-fluoroOhenyl)- ethyllpiperazine. 1.4 Hydrogen Oxalate. Monohvdrate 0.2 Diethyl etherate 1. Intermediate 1: 4-(1.2.4-Triazol-4-yl)phenylhvdrazine Prepared as described in WO 94/03446, Example 1. 2. Intermediate 2: l-l3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4- (H)-piperazine. 3.5 Hydrogen Oxalate (i) 5-(4-tert-Butyloxycarbonyl)piperazin-l-yl pentanal dimethyl acetal a) 5-Bromopentanal dimethyl acetal To a solution of 5 -bromovaleryl chloride (50g, 0.25 lmol) in anhydrous THF (500ml), at -78°C, was added hthium tri-tert-butoxyaluminohydride (1.0M solution in tetrahydrofuran, 300ml; 0.30mol), keeping the temperature below -70°C. The solution was stirred at -78°C for 5h and then quenched by dropwise addition of 2M hydrochloric acid (350ml). The mixture was warmed to room temperature and stirred for 16h. Diethyl ether (500ml) was added, the aqueous phase separated and extracted further with ether (x 2). The combined extracts were washed with saturated Na 2 CO3 solution (x 1), water (x 1) and brine (x 2), dried (Na 2 SO ) and evaporated to give 5-bromovaleraldehyde (37.5g, 91%). A solution of 5-bromovaleraldehyde (37.5g, 0.227mol) in methanol (250ml) and concentrated sulphuric acid (0.5ml) was stirred at room temperature for 3h. The solvent was removed under vacuum and to the residue was added K2CO3 solution (50ml) and diethyl ether (500ml). The aqueous layer was separated and re-extracted with ether (x 2). The combined extracts were washed with water and brine, dried (Na 2 SO 4 ) and evaporated. The crude product was chromatographed on silica gel eluting with diethyl ether/hexane (1:9) to give the title-acetal (27.5g, 57%). δ (250MHz, CDCls) 1.43-1.67 (4H, m, 2 of CH 2 ); 1.83-1.94 (2H, m, CH 2 ); 3.38 (6H, s, CH(OMe) 2 ); 3.42 (2H, t, J=7Hz, CH-Br), 4.37 (IH, t, J=7Hz, CH(OMe) 2 ). b) 5-(4-tert-Butyloxycarbonyl)piperazin-l-yl pentanal dimethyl acetal A mixture of 5 -bromo valer aldehyde dimethyl acetal (27.5g, 0.13mol), Na 2 CO 3 (20.7g, 0.195mol), sodium iodide (19.5g, 0.13mol) and tert-butyl- 1- piperazinecarboxylate (25.5g, 0.137mol), in dimethoxyethane (250ml), was heated at 100°C for 3h. Aluminium fofl was wrapped around the vessel to exclude hght. The mixture was cooled to room temperature and filtered. The filtrate was evaporated under reduced pressure and then EtOAc (50ml) added and the mixture filtered again to remove inorganic salts. The solvent was removed under vacuum and the residue chromatographed on silica gel eluting with EtOAc to give the title-product (25.7g, 63%). δ (250MHz, CDCI3) 1.29-1.71 (6H, m, 3 of CH 2 ); 1.46 (9H, s, OC(Me) 3 ); 2.31- 2.39 (6H, m, 3 of CH2); 3.32 (6H, s, CH(OMe)2); 3.41-3.45 (4H, m, 2 of CH 2 ); 4.36 (IH, t, J=6Hz, CH(OMe) 2 ). (ii) l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyn-4-(H)-piperazine. 3.5 Hydrogen Oxalate A mixture of Intermediate 1 (5.0g, 28.6mmol) and 5-(4-tert- butyloxycarbonyl)piperazin-l-yl pentanal dimethyl acetal (9.03g, 28.6mmol) in 4% sulphuric acid (150ml) was heated at reflux for 48h. The solution was cooled in an ice-bath, basified with sohd K2CO3 and extracted with butan-1-ol (x 3). The solvent was removed under vacuum and azeotroped with hexane (x 2). The crude product was purified by chromatography on silica gel eluting with CH2Cl2/ eOH/NH3 (30:8:1) to give the title-indole (3.9g, 44%). The 3.5 hydrogen oxalate salt was prepared using 200mg of free base: mp 90-92°C. (Found: C, 45.97; H, 4.76; N, 13.77. Ci7H2 2 N6.3.5(C 2 H2θ4) requires C, 46.08; H, 4.76; N, 13.43%); δ (360MHz, D2O) 2.12-2.24 (2H, m, CH 2 ); 2.93 (2H, t, J=7Hz, CH2); 3.46-3.76 (8H, m, 4 of CH 2 ); 7.37 (IH, dd, J=1.9 and 8.7Hz, Ar-H); 7.39 (IH, s, Ar-H); 7.66 (IH, d, J=8.7Hz, Ar-H); 7.82 (IH, d, J=1.9Hz, Ar-H); 9.13 (2H, s, Triazole-H). 3. Intermediate 3: 3-(Fluoro)phenethyl bromide a) 3-(Fluoro)phenethyl alcohol To a stirred solution of 3-fluorophenylacetic acid (5.0g, 32.0mmol) in diethyl ether (100ml), at -10°C, was added hthium aluminium hydride (32.4ml of a IM solution in diethyl ether, 32.4mmol), dropwise. The reaction mixture was aUowed to warm to +25°C and stirred for 1 h, before again cooling to -10°C, and quenching by addition of methanol (20ml) and 4M sodium hydroxide (20ml). The resulting slurry was filtered and the filtrate evaporated in vacuo. The crude product was chromatographed on silica gel eluting with CH∑Ch/MeOH NHa (80:8:1) to give 3- (fluoro)phenethyl alcohol (3.80g, 84%), δ (250MHz, CDCla) 2.87 (3H, t, J=6.5Hz, CH 2 ), 3.87 (3H, t, J=6.5Hz, CH2), 6.89-7.02 (3H, m, Ar-H), 7.23- 7.33 (IH, m, Ar-H). b) 3-(Fluoro)phenethyl bromide To a solution of 3-(fluoro)phenethyl alcohol (3.8g, 27.0mmol), in anhydrous dichloromethane (100ml), cooled to 0°C, was added carbon tetrabromide (11.25g, 34.0mmol) and triphenylphosphine (10.62g, 41.0mmol). After stirring for 0.5h the solvent was removed in vacuo and diethyl ether (100ml) was added to the residue. The resultant precipitate was removed by filtration, the filtrate evaporated under reduced pressure and the crude product chromatographed on silica-gel eluting with ethyl acetate/hexane (1: 1) to give 3-(fluoro)phenethyl bromide (5.5 lg, 100%), δ (250MHz, CDCls) 3.16 (2H, t, J=7.4Hz, CH2), 3.57 (2H, t, J=7.4Hz, CH 2 ), 6.91-7.01 (3H, m, Ar-H), 7.24-7.33 (IH, m, Ar-H). 4. l-.3-(5-q.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-r2-(3- fluorophenvDethyllpiperazine. 1.4 Hydrogen Oxalate. Monohydrate O.2 Diethyl etherate To a solution of l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-(H)- piperazine (0.20g, 0.65mmol), in isopropyl alcohol (10ml) and DME (30ml), was added K2CO3 (0.178g, 1.29mmol), sodium iodide (0.10g, 0.65mmol) and 3-(fluoro)phenethyl bromide (0.144g, 0.7 lmmol) and the mixture refluxed for 16h. The reaction mixture was cooled to room temperature and the solvent removed in vacuo. The residue was taken up into aqueous K2CO3 solution (20ml) and extracted with ethyl acetate (3x). The combined extracts were dried (MgSO 4 ) and evaporated, and the residue chromatographed on sihca gel, eluting with CΗ∑CL MeOΗ/NΗa (90:8:1) to give the title-compound (66mg, 24%). The hydrogen oxalate salt was prepared, mp 175-176°C, (Found: C, 57.98; Η, 6.18; N, 13.88. C2 5 Η 2 9NGF-1.4(C2Η2θ 4 ) 1.0Η2θ-0.2(diethyl ether) requires C, 58.08; H, 6.10; N, 14.20%), m/e 433 (M+l) + , δ (360MHz, De-DMSO) 1.94-2.04 (2H, m, CH 2 ), 2.66-3.16 (16H, m, 8 of CH 2 ), 6.98-7.12 (3H, m, Ar-H), 7.08-7.34 (3H, m, Ar-H), 7.50 (IH, d, J=8.7Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.01 (2H, s, Ar-H), 11.16 (IH, s, NH). Examples 2-5 were prepared using the procedures described for Example 1 starting from either the commerciaUy available phenethyl alcohols or the phenylacetic acid. EXAMPLE 2 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-r2-(2- fluorophenvDethyllpiperazine. 1.6 Hydrogen Oxalate. Monohydrate. 0.3 Diethyl etherate mp: 216-217°C, (Found: C, 57.28; H, 6.09; N, 13.25. C25H29N6F l.6(C2H2θ4) 1.0H 2 O-0.3(diethyl ether) requires C, 57.24; H, 6.08; N, 13.62%), δ (360MHz, De-DMSO) 1.96-2.06 (2H, m, CHa), 2.66-3.20 (16H, m, 8 of CH 2 ), 7.13-7.18 (2H, m, Ar-H), 7.25-7.37 (4H, m, Ar-H), 7.51 (1H, d, J=8.7Hz, Ar-H), 7.81 (IH, d, J=2.0Hz, Ar-H), 9.02 (2H, s, Ar-H), 11.18 (IH, s, NH). EXAMPLE 3 l-r3-(5-(1.2.4-Triazol-4-v -lH-indol-3-yl)propyll-4-r2-(4- fluorophenyl)ethyl]piperazine. 3.4 Hydrogen Oxalate mp: 201-202°C, (Found: C, 51.67; H, 5.05; N, 11.56. C25H 2 9NeF-3.4(C2H2θ4) requires C, 51.71; H, 4.89; N, 11.37%), m/e 433 (M+l) + , δ (250MHz, De-DMSO) 1.90-2.06 (2H, m, CH 2 ), 2.68-3.14 (16H, m, 8 of CH 2 ), 7.08-7.14 (2H, m, Ar-H), 7.24-7.34 (4H, m, Ar-H), 7.50 (IH, d, J=8.6Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.02 (2H, s, Ar-H), 11.17 (IH, s, NH). EXAMPLE 4 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-r2-(3- methoxyphenyl)ethyl]piperazine. 1.1 Hydrogen Oxalate. 0.7 Hydrate mp: 190-191°C, (Found: C, 60.88; H, 6.42; N, 14.92. C2eH32N 6 O- l.l(C2H2θ 4 )-0.7H2θ requires C, 60.89; H, 6.45; N, 15.11%), m/e 445 (M+l) + , δ (360MHz, De-DMSO) 1.90-2.02 (2H, m, CH 2 ), 2.66-3.10 (16H, m, 8 of CH 2 ), 3.74 (3H, s, OMe), 6.75-6.82 (3H, m, Ar-H), 7.18-7.03 (IH, m, Ar-H), 7.30-7.34 (2H, m, Ar-H), 7.50 (IH, d, J=8.5Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.02 (2H, s, Ar-H), 11.15 (IH, s, NH). EXAMPLE 5 l-r3-(5-Q.2.4-Triazol-4-yl)-lH-indol-3-yl)propyn-4-.2-(3- trifluoromethylphenvPethyllpiperazine. 2.0 Hydrogen Oxalate. Hemihydrate mp: 223-224°C, (Found: C, 53.57; H, 4.99; N, 12.42. C2eH29N6F3-2.0(C 2 H2θ4)-0.5H2θ requires C, 53.65; H, 5.10; N, 12.51%), m/e 483 (M+l) + , δ (360MHz, De-DMSO) 1.94-2.05 (2H, m, CH 2 ), 2.64-3.24 (16H, m, 8 of CH 2 ), 7.30-7.33 (2H, m, Ar-H), 7.50 (IH, d, J=8.6Hz, Ar-H), 7.51- 7.58 (3H, m, Ar-H), 7.62 (IH, s, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.01 (2H, s, Ar-H), 11.16 (IH, s, NH). EXAMPLE 6 l-.3-(5-Q.2.4-Triazol-4-yl H-indol-3-yl)propyll-4-.2-(3.4- difluorophenyl)ethyl]piperazine. 1.15 Hydrogen Oxalate. 0.3 Hydrate a) 3,4-(Difluoro)phenethyl bromide Prepared from 3,4-(difluoro)phenylacetic acid using the procedures described for Intermediate 3. δ (250MHz, CDCls) 3.12 (2H, t, J=7.3Hz, CH 2 ), 3.54 (2H, t, J=7.3Hz, CH 2 ), 6.90-7.16 (3H, m, Ar-H). b) l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-12-(3.4- difluorophenvDethyllpiperazine. 1.15 Hydrogen Oxalate. 0.3 Hydrate To a solution of l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-(H)- piperazine (0.2g, 0.65mmol), in anhydrous DMF (30ml), was added anhydrous triethylamine (0.13g, 1.29mmol), sodium iodide (0.09g, 0.65mmol), and 3,4-(difluoro)phenethyl bromide (0.157g, 0.71mmol) and the mixture heated at reflux for 16h. The reaction mixture was cooled to room temperature and partitioned between water (40ml) and ethyl acetate (150ml). The organic layer was separated and washed with water (2x) and brine (lx). The organic solution was dried (MgSO-i) and the solvent removed in vacuo. The crude product was chromatographed on silica gel eluting with CΗ 2 Cl 2 /MeOΗ/NΗ3 (90:8: 1) to give the title-compo- c. (0.05g, 20%). The hydrogen oxalate salt was prepared, mp 168-169°C, (Found: C, 58.67; H, 5.62; N, 15.02. C2sH28N6F2- 1.15(C 2 H2θ >0.3H 2 O requires C, 58.61; H, 5.57; N, 15.02%), m/e 451 (M+l) + , δ (360MHz, De-DMSO) 1.92- 2.03 (2H, m, CHa), 2.60-3.20 (16H, m, 8 of CH 2 ), 7.06-7.10 (IH, m, Ar-H), 7.29-9.37 (4H, m, Ar-H), 7.49 (IH, d, J=8.6Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.01 (2H, s, Ar-H), 11.16 (IH, s, NH). Examples 7 and 8 were prepared using the general procedures described for Example 6. EXAMPLE 7 l-l3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-r2-(2.4- difluorophenvDethyllpiperazine. 2.75 Hydrogen Oxalate. Hemihydrate mp: 208-209°C, (Found: C, 51.81; H, 4.92; N, 11.88. C25H28NeF2-2.75(C2H2θ 4 )-0.5H2θ requires C, 52.01; H, 5.14; N, 11.86%), m/e 451 (M+l) + , δ (250MHz, De-DMSO) 1.84-2.06 (2H, m, CH 2 ), 2.50-3.18 (16H, m, 8 of CH 2 ), 6.92-7.40 (5H, m, Ar-H), 7.47 (IH, d, J=8.6Hz, Ar-H), 7.76 (IH, d, J=2.0Hz, Ar-H), 8.99 (2H, s, Ar-H), 11.14 (IH, s, NH). EXAMPLE 8 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-.2-(3.5- difluorophenvPethyllpiperazine. 2.5 Hydrogen Oxalate. Hemihydrate mp: 223-224°C, (Found: C, 52.62; H, 5.31; N, 12.09. C25H28N 6 F2-2.5(C 2 H2O 4 )-0.5H2O requires C, 52.63; H, 5.01; N, 12.27%), m/e 451 (M+l) + , δ (360MHz, De-DMSO) 1.94-2.08 (2H, m, CH 2 ), 2.68-3.16 (16H, m, 8 of CH 2 ), 6.98-7.06 (3H, m, Ar-H), 7.30-7.36 (2H, m, Ar-H), 7.51 (IH, d, J=8.6Hz, Ar-H), 7.81 (IH, d, J=2.0Hz, Ar-H), 9.02 (2H, s, Ar-H), 11.16 (IH, s, NH). EXAMPLE 9 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-[2-(3-(oxazohdin-2-on-3- yDphenvDethyllpiperazine. 1.2 Hydrogen Oxalate. Monohydrate a) 3-Aminophenethyl alcohol To a solution of 3-nitrophenethyl alcohol (5.13g, 30.7mmol), in ethanol (100ml), was added a slurry of 10% Pd-C (0.5g), in water (4ml), and the mixture hydrogenated in a Parr flask, at 45psi for 0.75h. The catalyst was removed by filtration and the solvent evaporated to give 3- aminophenethyl alcohol (4.2g, 100%), mp 61-64°C, δ (360MHz, CDC1 3 ) 2.77 (2H, t, J=6.7Hz, CH2), 3.80 (2H, t, J=6.7Hz, CH2), 6.55-6.63 (3H, m, Ar-H), 7.08 (IH, dd, J=7.6 and 8.06Hz, Ar-H). b) 3-(Oxazolidin-2-on-3-yl)phenethyl alcohol To a solution of 3-aminophenethyl alcohol (2.0g, 14.6mmol) in dioxane (50ml) and water (25ml) was added an aqueous solution of sodium hydroxide (0.64g in 14.4ml of water, 16. lmmol), foUowed by chloroethyl chloroformate (2.19g, 15.3mmol). The mixture was stirred for 0.25h at room temperature and then NaOH solution added to pHl l and stirring continued for 0.25h. Further chloroethyl chloroformate (l.lg, 7.7mmol) was added foUowed, after 10 minutes, by NaOH solution to pHl l. The mixture was stirred for 0.25h and the solvents removed in vacuo. The residue was partitioned between ethyl acetate (2x100ml) and water (50ml) and the organic extracts combined, dried (Na2SO 4 ) and evaporated. The residue was chromatographed on sihca gel with 50% ethyl acetate/hexane to give the chloroethyl carbamate (3.6g, 100%). To a solution of sodium (85mg, 3.7mmol), in methanol (10ml), was added a solution of the preceding carbamate (0.9g, 3.7mmol), in methanol (10ml), and the mixture stirred at room tempaerature for 16h. The reaction mixture was partitioned between water (50ml) and ethyl acetate (4x50ml). The combined organic extract was dried (Na2SO 4 ), evaporated, and the residue chromatographed on sihca gel, eluting with ethyl acetate to give the title- oxazolidinone (0.628g, 82%), mp 82-85°C, δ (250MHz, CDCL) 2.90 (2H, t, J=6.5Hz, CH2), 3.89 (2H, t, J=6.5Hz, CH 2 ), 4.04-4.10 (2H, m, CH2), 4.46- 4.52 (2H, m, CH 2 ), 7.03 (IH, d, J=6.8Hz, Ar-H), 7.29-7.40 (2H, m, Ar-H), 7.48 (IH, s, Ar-H). c) 3-(Oxazoh din -9. -nn-3-yl)phenethyl bromide To a solution of the preceding alcohol (0.5g, 2.4mmol), in anhydrous dichloromethane (25ml), was added triphenylphosphine (0.95g, 3.6mmol) and carbon tetrabromide (l.OOg, 3.0mmol) and the mixture stirred at room temperature for 0.5h. The solvent was removed under vacuum and the residue was triturated with diethyl ether. The resultant sohd was removed by filtration and the filtrate evaporated. The residue was chromatographed on sihca gel eluting with ethyl acetate/hexane (1: 1) to give the tiύe-bromide (0.59g, 91%), mp 73-75°C, δ (360MHz, CDCI3) 3.18 (2H, t, J=7.5Hz, CH 2 ), 3.58 (2H, t, J=7.5Hz, CH2), 4.07 (2H, dd, J=6.5 and 8.3Hz, CH 2 ), 4.49 (2H, dd, J=6.5 and 8.3Hz, CH 2 ), 7.00 (IH, d, J=7.0Hz, Ar-H), 7.31-7.38 (2H, m, Ar-H), 7.51 (IH, s, Ar-H). d) l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyn-4-[2-(3-(oxazohdin-2- on-3-yl)phenyl)ethyllpiperazine. 1.2 Hydrogen Oxalate. Monohydrate A mixture of l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4(H)- piperazine (0.20g, 0.65mmol), 3-(oxazohdin-2-on-3-yl)phenethyl bromide (0.192g, 0.71mmol) and K2CO3 (98mg, 0.71mmol), in anhydrous DMF (5ml), was heated at 70°C for 1.5h. The mixture was cooled to room temperature and the solvent removed in vacuo. The residue was partitioned between CΗ2CI2 (2x50ml) and water (5ml). The combined extracts were dried (Na2SO ) and evaporated and the residue chromatographed on sihca gel with CHaCla/MeOH (90:10- 80:20) to give the title prod uct (0.217g, 67%). The hydrogen oxalate salt was prepared, mp 136°C (dec), (Found: C, 58.34; H, 6.34; N, 15.29. C28H 3 3N7O2-1.2(C 2 H 2 O4) 1.0H2O requires C, 58.36; H, 6.03; N, 15.67%), m/e 500 (M+l) + , δ (250MHz, De-DMSO) 1.88-2.06 (2H, m, CH 2 ), 2.60-3.17 (16H, m, 8 of CH 2 ), 4.04 (2H, dd, J=7.4 and 9.6Hz, CH 2 ), 4.43 (2H, dd, J=7.4 and 9.6Hz, CH 2 ), 7.00 (IH, d, J=7.5Hz, Ar-H), 7.27-7.52 (6H, m, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 9.03 (2H, s, Ar-H), 11.19 (IH, s, NH). EXAMPLE 10 l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyn-4-r2-(3- fluorophenyl)ethyl]piperazine. Dihydrogen Maleate. 0.4 Hydrate a) 1 - (3 -Fluorophenyl) - 2 -methox vethene Phenyllithium (98.3ml of a 1.8M solution in cyclohexane/diethyl ether, 177mmol) was added to a stirred suspension of (methoxymethyl)triphenylphosphonium chloride (60.82g, 177mmol) (note - dried overnight at 50°C in vacuo immediately prior to use), in diethyl ether (500ml) at 0°C under nitrogen. The sohd was seen to dissolve and a bright orange/brown coloration formed. The mixture was stirred at 0°C for 0.25h and then at room temperature for 0.5h. The mixture was cooled to -20°C and 3-fluorobenzaldehyde (20.0g, 16 lmmol) then added. The reaction mixture was aUowed to warm to room temperature and stirred overnight (16h). Saturated ammonium chloride solution (250ml) was added and the aqueous separated and extracted further with diethyl ether (x2). The combined ethereal layers were dried (MgSO 4 ), evaporated in vacuo and the residue distilled («60°C at 1.3mbar) to remove the majority of the phosphorous by-products. The distillate was then purified by column chromatography on silica gel, eluting with ethyl acetate/hexane (2:98) to give the title-era / ether as an E/Z mixture (10.7g, 44%), δ (250MHz,CDCl 3 ) 3.69 and 3.80 (total 3H, 2 of s, OCHs), 5.21 and 5.77 (total IH, 2 of d, J=7.0Hz and 13.0Hz respectively, C=CHz and C=CHE), 6.18 (d, J=7.0Hz, C=CHz), 6.78-7.41 (m, Ar-H and C=CHE). b) 3-Fluorophenylacetaldehvde Concentrated hydrochloric acid (45ml) was added to a stirred solution ofthe preceding enol ether (7.22g, 47.5mmol), in THF (225ml), at 0°C The mixture was stirred under nitrogen for 0.3h, at 0°C, and then at room temperature for 3h. Water was added and the volatiles were evaporated in vacuo. The residue was taken up in diethyl ether and the organic layer separated, washed with water (x2), saturated sodium bicarbonate solution (xl) and water (xl), dried (MgSO 4 ) and evaporated in vacuo to afford the ύ e-aldehyde (5.8 lg, 89%), δ (250MHz, CDCla) 3.71 (2H, d, J=2.2Hz, CH 2 ), 6.93-7.39 (4H, m, Ar-H), 9.76 (IH, t, J=2.lHz, CHO). This material was used without further purification in the next step. c) l-r3-(5-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyll-4-[2-(3- fluorophenvDethyllpiperazine. Dihydrogen Maleate. 0.4 Hydrate Acetic acid (3.5ml, 61. lmmol) and sodium cyanoborohydride (1.92g, 30.6mmol) were added successively to a stirred solution of l-[3- (5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4(H)-piperazine, in methanol (300ml), at 0°C. A solution of the preceding aldehyde (4.2 lg, 30.5mmol) in methanol (100ml) was added dropwise over 0.5h and the resulting mixture stirred at 0°C for a further 5 min before being brought up to room temperature. The solution was stirred at room temperature overnight (16.25h), whereupon TLC (CΗ 2 Cl2/MeOΗ/NΗ 3 60:8:1) showed formation of a less polar product, although some residual piperazine was also evident. Saturated potassium carbonate solution (150ml) was added and the solution decanted away from the inorganic sohds and evaporated in vacuo. The residue was taken up in ethyl acetate and combined with the inorganic material that had been taken up into water. The organic layer was separated, washed with saturated potassium carbonate solution (xl) and brine (x2), dried (MgSO ) and evaporated in vacuo. Column chromatography of the residue on silica, eluting with CH2Cl2/ eOH/NH3 (80:8:1) afforded the title- do/e (8.34g, 79%). The dihydrogen maleate salt was prepared by addition of a solution of maleic acid (2.87g, 24.7mmol) in methanol (12ml) to a solution of the free base (5.35g, 12.4mmol) in methanol (75ml). The salt precipitated out spontaneously. The mixture was cooled for 15 min, then filtered and the sohd washed with diethyl ether (150ml) and dried in vacuo to afford 7.59g of material which was recrystallised from boiling methanol (370ml) to afford the desired product (6.16g), mp 184°C, (Found C, 58.96; H, 5.69; N, 12.38. C25H29NeF-2(C 4 H 4 θ4)-0.4H2θ requires C, 58.99; H, 5.67; N, 12.51%); HPLC, chemical purity: Rt=6.19 min (98.9%) at λ=230nm on a Hichrom RPB column, gradient eluting with MeCN in 25mM phosphate 5nM PSA, pH3, with a flow rate of lml/min, δ (500MHz, d 4 - MeOH+TFA) 2.19-2.25 (2H, m, CH 2 ), 2.91-2.94 (2H, t, J=7.5Hz, CH 2 ), 3.07-3.11 (2H, m, CH 2 ), 3.29-3.32 (6H, m, 3 of CH 2 ), 3.45-3.48 (2H, m, CHa), 3.70 (4H, br s, 2 of CH 2 ), 6.30 (4H, s, maleate=CH), 7.01-7.10 (3H, m, Ar-H), 7.31-7.41 (3H, m, Ar-H), 7.59 (IH, d, J=8.5Hz, Ar-H), 7.94 (IH, d, J=2.0Hz, Ar-H), 9.83 (2H, s, Ar-H). EXAMPLE 11 l-r3-(5- midazol-l-yl)-lH-indol-3-yl)propyl1-4-r2-(3.4- difluorophenvDethyllpiperazine. 2.5 Hydrogen Maleate. 0.3 Hydrate 1. l-r3-(5-(Imidazol-l-yl)-lH-indol-3-yl)propyl1-4-(H)-piperazine a) 4-(Imidazol- l-yl)nitrobenzene To a stirred solution of imidazole (34. lg, O.δOmol) in DMF (300ml) under Ar, was added portionwise, over 23 minutes, 60% NaH in oil (20.02g, O.δOmol). The mixture was then stirred at room temperature for 18 minutes before adding dropwise, over 40 minutes, a solution of 1-fluoro- δ 4-nitrobenzene (70.62g, O.δOmol) in DMF (60ml). The mixture was then stirred at room temperature overnight. Water (600ml) was then added and the solid was filtered off, washed with water, then stirred in boiling ethyl acetate (400ml), aUowed to cool and filtered, washing the sohd with more ethyl acetate (50ml), then petroleum ether (250ml). The filtrate, now 0 containing more sohd, was refiltered and washed with petroleum ether. The combined sohds were dried in a vacuum desiccator overnight to give 90.14g (95%) of the title compound as a yeUow sohd. 6H (360MHZ, DMSO- de) 7.19 (IH, t, J=l.lHz), 7.97-8.03 (3H, m), 8.38 (2H, d, J=9.2Hz), 8.δ2 (IH, t). 5 b) 4-(Imidazol- l-yl)anihne. Dihydrochloride. A mixture of 4-(imidazol-l-yl)nitrobenzene (89.60g, 0.474mol) and 10% paUadium on carbon (4.50g) in ethanol (1200ml) and δN HCl (189ml) was hydrogenated in two batches at 40psi for 80 minutes. Water (4δ0ml) 0 was then added to dissolve the product and the catalyst was removed by filtration, washed with more water, and the combined filtrates were evaporated in vacuo, using finaUy a freeze drier, to give 10δ.4g (96%) of the title compound as a cream sohd. δH (2δOMHz, D2O) 7.22 (2H, d, J=8.8Hz), 7.3δ (IH, t, J=2.lHz), 7.44 (2H, d, J=9.0Hz), 7.δ9 (IH, t, 5 J=1.8Hz), 8.89 (IH, t, J=1.5Hz). c) 4-(Imidazol- l-yl)phenylhvdrazine. Dihydrochloride. To a cooled (-15°C) and stirred suspension of 4-(imidazol-l- yl)aniline dihydrochloride (20g, 86.16mmol) in concentrated hydrochloric 0 acid (100ml) was added dropwise, over 1 hour, a solution of sodium nitrite (6.25g, 9.05mmol) in water (40ml). After a further 10 minutes of stirring at -12°C, the mixture was quickly filtered to remove a sohd, and the filtrate was added portionwise to a cooled (-20°C) and stirred solution of tin (II) chloride dihydrate (lOOg) in concentrated hydrochloric acid (50ml) at such a rate as to maintain the internal temperature below -10°C (15 minutes). The mixture was aUowed to warm to 5°C over 30 minutes, and the sohd was coUected and washed with diethyl ether (4 x 100ml). The above sohd was suspended in water (200ml) and basified with 4N sodium hydroxide solution and extracted with ethyl acetate (δ x 500ml). The combined organic solutions were dried (Na2SO 4 ) and filtered. The filtrate was vigorously stirred whfle hydrogen chloride was being bubbled through the solution until a deep red mixture was obtained. Stirring was continued for a further 20 minutes to give a cream sohd which was coUected by filtration and dried over phosphorus pentoxide-potassium hydroxide under high vacuum to leave 12.7g (60%) of the title compound; δ H (360MHz, DMSO-de) 7.20 (2H, d, J=9.0Hz), 7.73 (2H, d, J=9.0Hz), 7.91 (IH, t, J=1.5Hz), 8.23 (IH, t, J=1.7Hz), 9.71 (IH, t, J=1.3Hz). d) l-r3-(5-(Imidazol-l-yl)-lH-indol-3-vI)propyl]-4-(H)-piperazine Prepared from 4-(imidazol-l-yl)phenylhydrazine and 5-(4-tert- butyloxycarbonyl)piperazin-l-yl pentanal dimethyl acetal using the procedure described for Example 1, Intermediate 2, δ (250MΗz, Dβ- DMSO) 1.86-1.97 (2H, m, CH 2 ), 2.37-3.66 (12H, m, 6 of CH 2 ), 4.23 (IH, br s, NH), 7.20 (IH, s, Ar-H), 7.35-7.40 (2H, m, Ar-H), 7.56 (IH, d, J=8.6Hz, Ar-H), 7.77 (IH, d, J=2.0Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar- H), 8.24 (IH, s, Ar-H), 11.11 (IH, s, NH). 2. l-.3-(5-αmidazol-l-yl)-lH-indol-3-yl)propyn-4-.2-(3.4- difluorophenvDethyllpiperazine. 2.5 Hydrogen Maleate. 0.3 Hydrate The title compound was prepared from 3,4- dϋluorophenylacetaldehyde and l-[3-(5-(imidazol- l-yl)-lH-indol-3- yl)propyl]-4-(H)-piperazine using the procedure described in Example 10. The 2.5 hydrogen maleate 0.3 hydrate salt was prepared, mp 143°C, (Found: C, 58.07; H, 5.19; N, 9.39. C26H29N5F2. 2.5(C 4 H 4 O 4 ). O.3H2O requires C, 58.03; H, δ.26; N, 9.40%), m/e 450 (M+l) + , δ (360MHz, De-DMSO) 1.96-2.06 (2H, m, CH 2 ), 2.50-3.70 (16H, m, 8 of 5 CH 2 ), 6.12 (maleate-H's), 7.06-7.10 (IH, m, Ar-H), 7.28-7.38 (4H, m, Ar-H), 7.δ2 (IH, d, J=8.6Hz, Ar-H), 7.54 (IH, s, Ar-H), 7.83 (IH, d, J=2.0Hz, Ar-H), 7.97 (IH, d, J=2.0Hz, Ar-H), 8.91 (IH, s, Ar-H), 11.19 (IH, s, NH). 10 EXAMPLE 12 l-.3-(5-qmidazol-l-yl)-lH-indol-3-yl)propyl1-4-.2-(3- fluorophenvDethyllpiperazine. 2.δ Hydrogen Maleate. Hemihydrate Prepared from l-[3-(δ-(imidazol-l-yl)-lH-indol-3-yl)propyl]-4-(H)- lδ piperazine and 3-fluorophenylacetaldehyde using the procedure described for Example 10. The 2.5 hydrogen maleate hemihydrate salt was prepared, mp 158-lδ9°C, (Found: C, δ9.16; Η, δ.62; N, 9.71. C26Η30N5F. 2.δ(C 4 H 4 O 4 ).0.δH 2 O requires C, δ9.17; H, δ.66; N, 9.58%), m/e 432 (M+l) + , δ (250MHz, De-DMSO) 1.90-2.08 (2H, m, CH2), 2.δ4- 20 3.60 (16H, m, 8 of CH2), 6.11 (maleate-H's), 6.98-7. lδ (3H, m, Ar-H), 7.29-7.39 (3H, m, Ar-H), 7.51-7.54 (2H, m, Ar-H), 7.84 (IH, d, J=2.0Hz, Ar-H), 7.97 (IH, s, Ar-H), 8.90 (IH, s, Ar-H), 11.20 (IH, s, NH). Examples 13 and 14 were prepared from l-[3-(5-(2-methylimidazol-l- 2δ yl)-lH-indol-3-yl)propyl]-4-(H)-piperazine and the appropriate phenylacetaldehyde using the procedures described for Example 11. EXAMPLE 13 30 l-.3-(δ-(2-Methvhmidazol-l-yl)-lH-indol-3-yl)propyl1-4-.2-(3- fluorophenvDethyllpiperazine. 2.75 Ηvdrogen Maleate mp: 160-161°C, (Found: C, 59.δ2; H, 5.74; N, 9.46. C27H32N5F. 2.75(C 4 H 4 0 4 ) requires C, δ9.68; H, δ.67; N, 9.16%), m/e 446 (M+l) + , δ (2δOMHz, De-DMSO) 1.88-2.06 (2H, m, CH2), 2.δ4-3.60 (16H, m, 8 of CH2), 6.08 (maleate-H's), 6.98-7.40 (6H, m, Ar-H), 7.56 (IH, d, 5 J=8.6Hz, Ar-H), 7.70 (IH, d, J=2.0Hz, Ar-H), 7.75 (IH, d, 2.0Hz, Ar-H), 7.80 (IH, d, J=2.0Hz, Ar-H), 11.33 (IH, s, NH). EXAMPLE 14 10 l-r3-(5-(2-Methylimidazol-l-yl)-lH-indol-3-yl)propyn-4-r2-(3.4- difluorophenyl)ethyl]piperazine. 2.75 Hydrogen Maleate mp: 148-149°C, (Found: C, 58.29; H, 5.51; N, 8.72. C27H31N5F2. 2.75(C 4 H 4 0 4 ) requires C, δ8.31; H, 5.41; N, 8.95%), m/e 464 (M+l) + , δ (2δOMHz, De-DMSO) 1.88-2.06 (2H, m, CH 2 ), 2.δ2-3.60 (16H, m, 8 of lδ CH 2 ), 6.09 (maleate-H's), 7.06-7.14 (IH, m, Ar-H), 7.25 (IH, dd, J=8.6 and 2.0Hz, Ar-H),7.30-7.42 (3H, m, Ar-H), 7.57 (IH, d, J=8.6Hz, Ar-H), 7.71 (IH, d, J=2.0Hz, Ar-H), 7.76 (IH, d, J=2.0Hz, Ar-H), 7.79 (IH, d, J=2.0Hz, Ar-H), 11.34 (IH, s, NH). 20 EXAMPLE 15 l-r3-(5-(1.2.4-Triazol-l-ylmethyl)-lH-indol-3-yl)propyll-4-f2-(3- fluorophenvDethyllpiperazine. Dihydrogen Maleate 25 1. 3-[5-(1.2.4-Triazol-l-ylmethyl)-lH-indol-3-vnpropan-l-ol 3,4-Dihydro-2H-pyran (3.9ml, 42.7mmol) was added to a stirred solution of 4-(l,2,4-triazol-l-ylmethyl)phenyl hydrazine (EP 497,δl2; 4.0g, 21. lmmol) in dioxane/water/5N ΗC1 (38ml/ 14ml/4.7ml) and stirred at room temperature for 1.75 h. The solution was then refluxed for 1.5 h and 30 the solvent removed under vaccum. The residue was taken up into CΗ 2 C1 2 and saturated aqueous K-CO3 solution. The aqueous was separated and further extracted with CH2CI2 (x4). The combined organic extracts were dried (MgS0 4 ) and evaporated and the residue chromatographed on silica gel eluting with CH 2 Cl 2 /MeOH/NH3 (80:8:1) to give the title- doZe (0.919g, 17%), δ (2δOMHz, CDCI3) 1.91-2.03 (2H, m, CH 2 ), 2.84 (2H, t, δ J=7.9Hz, CH2), 3.73 (2H, t, J=7.9Hz, CH2), δ.43 (2H, s, CH 2 ), 7.04 (IH, d, J=2.3Hz, Ar-H), 7.11 (IH, dd, J=2.3 and 8.3Hz, Ar-H), 7.3δ (IH, d, J=8.3Hz, Ar-H), 7.δ8 (IH, s, Ar-H), 7.97 (IH, s, Ar-H), 8.02 (IH, s, Ar-H), 8.18 (IH, s, NH). 10 2. 4-[2-(3-Fluorophenyl)ethvnpiperazine Sodium cyanoborohydride (2.9δg, 47.03mmol) was added portionwise to a solution of iV-BOC-piperazine (4.38g, 23.δ2mmol) and glacial acetic acid (4.24g, 70.δδmmol), in methanol (200ml), at -10°C. A solution of 3-fluorophenylacetaldehyde (3.89g, 28.23mmol) in lδ methanol (20ml) was added dropwise and the mixture then warmed to +2δ°C and stirred for 16h. The solution was basified with saturated K-2CO3 solution and the methanol removed under vacuum. The aqueous was extracted with CH12CI2 (2x200ml) and the combined extracts washed with brine (x2), dried (Na2SO ) and evaporated to give 0 5.29g of product (73%). Formic acid (100ml) was added to the preceding adduct (4.84g, 15.7mmol) and the solution stirred at room temperature for 16h. The solvent was removed under vacuum, the residue basified by addition of saturated K2CO3 solution, and extracted into n-butanol (50ml). The butanol was removed under vacuum and 5 the residue chromatographed on sihca gel eluting with CH 2 Cl 2 /MeOH/NH3 (40:8:1) to give the title- . rod uct (2.35g, 72%), δ (360MHz, CDCI3) 2.δ0 (4H, br s, 2 of CH 2 ), 2.56-2.63 (2H, m, CH 2 ), 2.78-2.83 (2H, m, CH 2 ), 2.92-2.94 (4H, m, 2 of CH 2 ), 6.86-6.99 (3H, m, Ar-H), 7.20-7.27 (IH, m, Ar-H). 0 3. l-r3-(δ-(1.2.4-Triazol-l-ylmethyl)-lH-indol-3-yl)propyll-4-r2-(3- fluorophenvPethyllpiperazine. Dihydrogen Maleate Methanesulphonyl chloride (0.118g, 1.03mmol) was added to a stirred solution of 3-[δ-(l,2,4-triazol-l-ylmethyl)-lH-indol-3-yl]propan- δ l-ol (0.22g, 0.86mmol) and triethylamine (0.104g, 1.03mmol), in anhydrous TΗF (30ml) at +δ°C. The solution was warmed to room temperature and stirred for l.δh. The solvent was removed under vacuum and the residue partitioned between CΗ 2 C1 2 (2x7δml) and water (30ml). The combined extracts were dried (Na 2 SO 4 ) and 10 evaporated and the residue redissolved in anhydrous THF (20ml). To the solution was added 4-[2-(3-fluorophenyl)ethyl]piperazine (0.339g, 1.63mmol), K2CO3 (0.22δg, 1.63mmol) and sodium iodide (0.24δg, 1.63mmol) and the mixture refluxed for 2 h. The solvent was removed under vacuum and the residue partitioned between CH2CI2 (2x100ml) lδ and water (40ml). The combined extracts were dried (Na2SO 4 ) and evaporated and the resulting residue chromatographed on sihca gel eluting with CH 2 Cl 2 /EtOH/NH 3 (80:δ:0.δ) to give the title-inc-o-e (0.269g, 70%). The dihydrogen maleate salt was prepared, mp 187°C, (Found: C, 60.01; H, δ.63; N, 12.12. 2(C4H 4 O4) requires C, 0 60.17; H, δ.79; N, 12.38%), m/e 447 (M+l) + , δ (360MHz, De-DMSO) 1.90-2.02 (2H, m, CH 2 ), 2.δ4-3.70 (16H, m, 8 of CH 2 ), δ.44 (2H, s, CH 2 ), 6.14 (maleate-H's), 7.00-7.14 (4H, m, Ar-H), 7.19 (IH, s, Ar-H), 7.31- 7.36 (2H, m, Ar-H), 7.δ2 (IH, s, Ar-H), 7.95 (IH, s, Ar-H), 8.60 (IH, s, Ar-H), 10.90 (IH, s, NH). 5 EXAMPLE 16 l-r3-(5-(1.2.4-Triazol-l-ylmethyl)-lH-indol-3-yl)propyll-4-r2-(3.4- difluorophenvDethyllpiperazine. Dihydrogen Maleate 30 The title compound was prepared from 3-[5-(l,2,4-triazol-l- ylmethyl)-lH-indol-3-yl]propan-l-ol and 4-[2-(3,4- difluorophenyl)ethyl]piperazine using the procedures described for Example lδ. The dihydrogen maleate salt was prepared, mp 178- 179°C, (Found: C, δ8.43; H, 5.43; N, 12.04. CaeHsoNeFa. 2.0(C 4 H 4 O 4 ) requires C, 58.61; H, δ.δO; N, 12.06%), m/e 46δ (M+l) + , δ (2δOMHz, δ CDCI3 on free base) 1.88-2.04 (2H, m, CH2), 2.38-2.82 (16H, m, 8 of CH 2 ), δ.43 (2H, d, CH2), 6.86-7.16 (δH, m, Ar-H), 7.36 (IH, d, J=8.4Hz, Ar-H), 7.δ7 (IH, s, Ar-H), 7.96 (IH, s, Ar-H), 8.00 (IH, s, Ar-H), 8.11 (IH, br s, NH). 10 EXAMPLE 17 l-r3-(δ-(1.2.4-Triazol-4-yl)-lH-indol-3-yl)propyn-4-r2-(3-fluorophenyl)- ethyllpiperazine. dicitrate salt lδ l-[3-(δ-(l,2,4-Triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3- fluorophenyl)ethyl]piperazine was dissolved in methanol heated to δ8°C under a nitrogen atmosphere. Citric acid, in methanol at δ8°C, was added, and the solution aUowed to cool to ambient temperature, then left to stand for 16 hours. The mixture was filtered and the sohd dried 20 in vacuo at δ0°C to give the title compound, mp 176°C (dec).

Claims: CLAIMS: A compound of formula I, or a salt or prodrug thereof: wherein X represents a group of formula (Xa), (Xb) or (Xc): *Y N N I N- N-CH, N- 10 (Xa) (Xb) (Xc) in which Y represents nitrogen or C-R 4 ; R 1 represents fluoro, chloro, trifluoromethyl, Ci e alkoxy or a group of formula (a): lδ , ΓΛ o o (a) R 2 and R 3 independently represent hydrogen, halogen, trifluoromethyl or Ci-β alkoxy; and 20 R 4 represents hydrogen or Ci e alkyl. 2. A compound as claimed in claim 1 wherein X represents a group of formula (Xa). 3. A compound as claimed in claim 1 or claim 2 represented by δ formula IIA, and salts and prodrugs thereof: (IIA) wherein R 1 , R 2 and R 3 are as defined in claim 1. 10 4. A compound as claimed in claim 1 represented by formula IIB, and salts and prodrugs thereof: (IIB) lδ wherein R 1 , R 2 and R 3 are as defined in claim 1. δ. A compound as claimed in claim 1 represented by formula IIC, and salts and prodrugs thereof: 0 (HC) wherein Y 1 represents nitrogen, CH or C-methyl; and R 1 , R 2 and R 3 are as defined in claim 1. 6. A compound as claimed in any one of the preceding claims wherein R 1 represents fluoro or trifluoromethyl. 7. A compound as claimed in any one of the preceding claims wherein R 2 and R 3 independently represent hydrogen or fluoro. 8. A compound as claimed in any one of the preceding claims wherein R 2 is hydrogen and R 3 is other then hydrogen. 9. A compound as claimed in any one of claims 1 to 7 wherein R 2 and R 3 are both hydrogen. 10. A comp oun d selecte d from : l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(2-fluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(4-fluorophenyl)- ethyl]piperazine; l-[3-(5-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-methoxyphenyl)- ethyl]piperazine; l-[3-(δ-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-trifluoromethyl- phenyl)ethyl]piperazine; l-[3-(δ-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)- ethyl]piperazine; δ l-[3-(δ-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(2,4-difluorophenyl)- ethyl]piperazine; l-[3-(δ-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3,δ-difluorophenyl)- ethyl]piperazine; l-[3-(δ-(l,2,4-triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3-(oxazohdin-2-on-3- 10 yl)phenyl)ethyl]piperazine; and salts and prodrugs thereof. 11. A compound selected from: l-[3-(δ-(imidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4-difluorophenyl)- lδ ethyljpiperazine; l-[3-(δ-(imidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)- ethyljpiperazine; l-[3-(δ-(2-methyhmidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3- fluorophenyl)ethyl]piperazine; 0 l-[3-(δ-(l,2,4-triazol-l-ylmethyl)-lH-indol-3-yl)propyl]-4-[2-(3,4- difluorophenyl)ethyl]piperazine; l-[3-(δ-(2-methyhmidazol-l-yl)-lH-indol-3-yl)propyl]-4-[2-(3,4- difluorophenyl) ethyl]pip erazine; l-[3-(δ-(l,2,4-triazol-l-ylmethyl)-lH-indol-3-yl)propyl]-4-[2-(3- δ fluorophenyl)ethyl]piperazine; and salts and prodrugs thereof. 12. l-[3-(5-(l,2,4-Triazol-4-yl)-lH-indol-3-yl)propyl]-4-[2-(3- fluorophenyl)ethyl]piperazine, or a salt thereof. 0 13. A salt of the compound as claimed in claim 12 selected from the group consisting of the oxalate, maleate and citrate salts. 14. The dicitrate salt of l-[3-(δ-(l,2,4-triazol-4-yl)- lH-indol-3- δ yl)propyl]-4-[2-(3-fluorophenyl)ethyl]pipera_sine. 15. A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceuticaUy acceptable salt thereof or a prodrug thereof in association with a pharmaceuticaUy 0 acceptable carrier. 16. A compound of formula I as defined in claim 1 or a pharmaceuticaUy acceptable salt thereof or a prodrug thereof for use in therapy. 5 17. The use of a compound of formula I as defined in claim 1 or a pharmaceuticaUy acceptable salt thereof or a prodrug thereof for the manufacture of a medicament for the treatment and/or prevention of chnical conditions for which an agonist of 5-HTID receptors selective for 0 the δ-HTiDα subtype thereof is indicated. 18. A process for the preparation of a compound as claimed in claim 1, which comprises: δ (A) reacting a compound of formula III with a compound of formula IV: σn) (IV) wherein X, R 1 , R 2 and R 3 are as defined in claim 1, and L 1 represents a suitable leaving group; or (B) reacting a compound of formula III as defined above with a compound of formula V: (V) wherein R 1 , R 2 and R 3 are as defined in claim 1; in the presence of a reducing agent; or (C) reacting a compound of formula III as defined above with a carboxyhc acid derivative of formula VI: (VI) wherein R 1 , R 2 and R 3 are as defined in claim 1; in the presence of a condensing agent; foUowed by treatment with a reducing agent; or (D) reacting the appropriate compound of formula VII: (VII) wherein X is as defined in claim 1; with a compound of formula XII, or a carbonyl-protected form thereof: wherein R 1 , R 2 and R 3 are as defined in claim 1; or (E) reacting a compound of formula XIV: (XIV) wherein R 1 , R 2 and R 3 are as defined in claim 1; with a compound of formula XV: (XV) wherein X is as defined in claim 1; or (F) reducing a compound of formula XVIII: (XVIII) 10 wherein X, R 1 , R 2 and R 3 are as defined in claim 1. 19. A method for the treatment and/or prevention of chnical conditions for which an agonist of δ-HT receptors selective for the δ-HTiDα subtype thereof is indicated, which method comprises lδ administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1 or a pharmaceuticaUy acceptable salt thereof or a prodrug thereof.

Inventors: JELLEY RICHARD ALEXANDER, MACLEOD ANGUS MURRAY, REEVE AUSTIN JOHN, STERNFELD FRANCINE, STREET LESLIE JOSEPH, JELLEY, RICHARD, ALEXANDER, MACLEOD, ANGUS, MURRAY, REEVE, AUSTIN, JOHN, STERNFELD, FRANCINE, STREET, LESLIE, JOSEPH
Applicants: JELLEY RICHARD ALEXANDER, MACLEOD ANGUS MURRAY, MERCK SHARP & DOHME, REEVE AUSTIN JOHN, STERNFELD FRANCINE, STREET LESLIE JOSEPH, JELLEY, RICHARD, ALEXANDER, MACLEOD, ANGUS, MURRAY, MERCK SHARP & DOHME LIMITED, REEVE, AUSTIN, JOHN, STERNFELD, FRANCINE, STREET, LESLIE, JOSEPH
Application year: 1996
Main classification: C07D403
IPC codes: A61K31, A61P25, A61P43, C07D403, C07D413, C07D521